Personalized treatment in advanced ALK-positive non-small cell lung cancer: From bench to clinical practice

Antonio Passaro, Chiara Lazzari, Niki Karachaliou, Gianluca Spitaleri, Alessia Pochesci, Chiara Catania, Rafael Rosell, Filippo de Marinis

Research output: Contribution to journalReview articlepeer-review

Abstract

The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second- or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-naïve ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed.

Original languageEnglish
Pages (from-to)6361-6376
Number of pages16
JournalOncoTargets and Therapy
Volume9
DOIs
Publication statusPublished - Oct 17 2016

Keywords

  • Alectinib
  • ALK
  • Brain metastases
  • Brigatinib
  • Ceritinib
  • Crizotinib
  • Lorlatinib
  • NSCLC

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Personalized treatment in advanced ALK-positive non-small cell lung cancer: From bench to clinical practice'. Together they form a unique fingerprint.

Cite this